EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

THE IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS(NASH):A VIEW FROM ACE GASTROENTEROLOGIST

Akashdeep Sikdar*

ABSTRACT

NASH and Covid19

(SARS-CoV-2) pandemic highlighted the importance of an effective host immune response. COVID-19, which can involve a number of diverse symptoms, including immune dysregulation and cytokine storm. Ongoing worldwide obesity pandemic that has led to insulin resistance, diabetes, and chronic liver disease (CLD), becoming a major public health burden. CLD is most commonly caused by chronic hepatitis B and C, alcohol-associated liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD). CLD can further led to inflammation (nonalcoholic steatohepatitis [NASH]), fibrosis, and finally cirrhosis and hepatocellular carcinoma (HCC) as end-stage diseases. Cirrhosis, viral hepatitis, and HCC are responsible for approximately 2 million deaths per year worldwide. Covid-19 have caused significant morbidity and mortality through increase inflammation and thrombosis. Non-alcoholic fatty liver disease and non- alcoholic steatohepatitis are states of chronic inflammation and indicate advanced metabolic disease. Hospitalizations for Covid-19 have disrupted thousands of lives. Obesity and metabolic disease appear to be the most significant modifiable risk factors for poor outcomes from Covid- 19. Given Covid-19’s pathophysiology through inflammation, NAFLD/NASH patients are at higher risk of poor outcomes from Covid-19. Here we discuss these serious healthcare burden with ace gastroenterologist Dr. Pardha Devaki. He received his medical education from Gandhi Medical College in Hyderabad, India. Dr. Devaki completed his Medicine Residency at Wayne State University/Detroit Medical Center in Detroit, Michigan, United States. He also completed his Gastroenterology and Hepatology Fellowship at Cleveland Clinic Foundation in Cleveland, Ohio. Currently Dr. Devaki is affiliated with Mercy Hospital Rogers. Below are excerpts from the discussion with Dr. Devaki.

Keywords: .


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • EJPMR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 issue has been successfully launched on 1 FEBRUARY 2024.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia